The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EMN 2018 | Patient fitness is a better criterion for treatment than age in MM
While it is understandable that elderly patients with multiple myeloma (MM) are generally excluded from more aggressive treatments, Mohamad Mohty, MD, PhD, of University Pierre & Marie Curie, France, speaking from the 1st European Myeloma Network (EMN) Meeting, in Turin, Italy, explains how, with the proper screening tests, elderly MM patients can tolerate and respond to treatment just as well as younger patients, and calls for improvements and refinements to the patient screening process to allow capable elderly patients to be treated.
